Clinical trials: Neoplasms, Metastatic
Advanced Gastric or EGJ Cancer
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
This clinical trial will evaluate whether it is beneficial in terms of prolongation of survival to combine FOLFIRI (standard treatment) with ramucirumab compared to the standard treatment of ramucirumab plus paclitaxel in…
- Trial name
- RAMIRIS (NCT03081143)
- Testing
- FOLFIRI, Ramucirumab, Paclitaxel
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 429 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Nasopharyngeal Carcinoma
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
- Trial name
- NCT03558191
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042874
- Testing
- alvocidib, irinotecan hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
The primary goal is to determine the maximum tolerated dose (MTD) of the combination of T-DM1 and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously treated with taxanes and…
- Trial name
- THELMA (NCT02562378)
- Testing
- Trastuzumab and non-pegylated liposomal doxorubicin
- Where
- 4 sites in France, Spain
- Volunteers
- 15 people
- Sponsor
- MedSIR
Metastatic Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
This is a prospective, single-center, open-label investigator-initiated study designed to evaluate the safety, tolerability, radiation dosimetry, biodistribution, and preliminary antitumor activity of [177Lu]Lu-RTX-2358 in…
- Trial name
- NCT07689643
- Testing
- [177Lu]Lu-RTX-2358
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Renal Cell Carcinoma
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
High-dose interleukin 2 (Proleukin, Novartis) (IL-2) is approved by the U.S Food and Drug Administration (FDA) for the treatment of metastatic kidney cancer and is a standard treatment of this disease.
- Trial name
- SELECT (NCT00554515)
- Testing
- HD IL2
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Beth Israel Deaconess Medical Center
Kidney Cancer, Melanoma (Skin)
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00004135
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma, Brain Metastases
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included.
- Trial name
- NCT03332589
- Testing
- E6201, E6201 plus dabrafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Spirita Oncology, LLC
Neoplasms
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
- Trial name
- NCT01973868
- Testing
- Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Bayer
Metastatic Hormone Naive Prostate Cancer
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic…
- Trial name
- UpFrontPSMA (NCT04343885)
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 12 sites in Australia
- Volunteers
- 130 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Prostate Cancer
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether mitoxantrone and prednisone are more effective with or without prinomastat in…
- Trial name
- NCT00003343
- Testing
- endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Pfizer
Melanoma
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
- Trial name
- THERAVAC (NCT01331915)
- Testing
- Theravac
- Where
- Belgium
- Volunteers
- 23 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer…
- Trial name
- TROPION-Lung08 (NCT05215340)
- Testing
- Datopotamab Deruxtecan, Pembrolizumab
- Where
- 234 sites in United States, Argentina and 26 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
The aim of the study is to evaluate the efficacy of the combination of lenvatinib with pembrolizumab, and to establish a safe and effective systemic treatment regimen for patients with metastatic anaplastic thyroid cancer (ATC) /…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage
- Trial name
- NCT04731740
- Testing
- Lenvatinib, Pembrolizumab, Chemotherapy
- Where
- Russia
- Sponsor
- Saint Petersburg State University, Russia
Solid Cancers
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with…
- Trial name
- NCT00927589
- Testing
- carboplatin, docetaxel, trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 59 people
- Sponsor
- Genentech, Inc.
Carcinoma, Islet Cell, Carcinoma, Pancreas
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received…
- Trial name
- NCT00428597
- Testing
- sunitinib malate
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Colorectal Neoplasms
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01082315
- Testing
- Erbitux (Cetuximab)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.